Kornimate/medical-research-clean huggingface dataset:
preferences for services in a patient's first six months on antiretroviral therapy for hiv in south africa

Conditions: HIV

Summary: with the advent of universal eligibility for hiv treatment ("treat all") and same-day and community-based antiretroviral therapy (art) initiation, retention in care after a patient has started art remains the main challenge to achieving optimal outcomes in hiv treatment programs. consistently across both time and geography, the highest risk for loss from care is during a patient's first six months after art initiation, with about quarter of all patients not retained by the end of month 6. one of the reasons for the high attrition from care in this early retention period is that the model of care offered to most newly-initiating and re-initiating patients has barely evolved from its original outlines. patients in their first six months on art are generally not eligible for lower-intensity, patient-centered "differentiated service delivery" models that make remaining in care easier for experienced patients. instead, most early patients must still make multiple clinic visits that include clinical consultations with providers, and most can receive only 1-2 month supplies of medications at a time. this protocol is for the prefer-south africa study, an activity of the retain6 project. retain6 aims to develop new models of care for patients' first six months on art. prefer-south africa will collect data on patients' characteristics, clinical and non-clinical needs, and preferences for different types of services during their first six months after initiating art. the investigators will conduct an observational, prospective cohort survey of newly-initiated or re-initiated adult art patients at a selected set of 18 healthcare facilities in south africa. results are expected to inform the design of better models of service delivery for the early treatment period.


Eligibility criteria:
inclusion criteria: * living with hiv and on art for 0-6 six months at the study site * ≥ 18 years old (18 and older considered adult for research purposes in south africa) * presented at the study site for routine hiv-related care * provide written informed consent to participate. * for patients providing a dried blood spot specimen, initiating or re-initiating art at the study enrollment visit. exclusion criteria: * unable to communicate in any of the languages into which the questionnaire has been translated or that is known to the research assistant * not physically, mentally, or emotionally able to participate in the study, in the opinion of the investigators or study staff * unwilling to take the time required to complete the questionnaire on the day of consent

Keywords: hiv antiretroviral treatment differentiated service delivery retention in care
using an adjustable compression garment for secondary upper limb lymphoedema

Conditions: Lymphedema of Upper Arm

Summary: this is a pilot randomised controlled trial investigating the use of an adjustable compression garment in the treatment of patients with breast cancer related upper limb lymphoedema. this study will be conducted as part of a msc qualification at the institute of technology sligo in ireland with all therapy sessions taking place in the physiotherapy department of sligo university hospital (formerly sligo general hospital). the study will be conducted in conjunction with sligo university hospital and it has attained ethical approval through the relevant university hospital ethics committee.

the experimental group will receive 5 treatments followed by a final assessment on the 6th visit over a 3 week period: participants will receive manual lymphatic drainage for 40 minutes. they will then put on an adjustable compression sleeve (juzo varocare adjustable compression system). patients will be re-measured before the fourth treatment and again on session 6. at this point patients will receive a standard arm compression sleeve. this will be worn in alternation with their adjustable compression sleeve over the following 6 months. patient will have their limb volume re-measured at the 6 month review. the control group will receive 5 treatments followed by a final assessment on the 6th visit over a 3 week period: participants will receive manual lymphatic drainage for 40 minutes. they will then have their arm wrapped in coban compression bandaging which will stay on until their next treatment. this will occur twice weekly for a period of 3 weeks. patients will be re-measured before the fourth treatment and again on session 6. at this point they will attend occupational therapy where they will receive 2 standard arm compression sleeves. the patient wears 1 sleeve every day over the following 6 months. patient will have their limb volume re-measured at the 6 month review.

Eligibility criteria:
inclusion criteria: * upper limb lymphoedema (secondary to breast cancer) diagnosed by a consultant * aged \> 18 years. * males and females. * stage 2 lymphoedema. * \>10% volume difference between upper limbs. * cognitive ability to understand the programme. exclusion criteria: * involvement in other studies or rehabilitation programmes. * active infection disease progression. * congestive cardiac failure. * non-english speakers. * under 18's. * poor cognition for treatment compliance or consent. * pregnant, or currently breast feeding.

Keywords: breast cancer related lymphoedema. compression bandaging.
efficacy of tca effect on varicella atrophic scars

Conditions: Atrophic Varicella Scar

Summary: this study aims to determine the efficacy of 70% trichloroacetic acid on atrophic scars of varicella

high concentration trichloroacetic acid peeling has been shown to be effective in treating and flattening the atrophic acne scars. according to the lack of an effective and low cost therapy for removing these relative common and nuisance lesions; we aimed to answer that whether we could achieve the same results from 70% tca on atrophic varicella scars.

Eligibility criteria:
inclusion criteria: * atrophic varicella scar on face exclusion criteria: * active varicella infection * active herpetic infection * previous history of keloid formation

Keywords: trichloroacetic acid varicella scar
evaluation of impact of disease on quality of life, education and socio-professional integration of adults and parents of children living with sickle- cell disease in france

Conditions: Sickle-cell Disease (SCD)

Summary: sickle cell disease (scd) is the most common genetic disease in france. its consequences on patient's life-course and quality of life need to be precisely identified among french patients and their family to be able to improve patients care according to their specific needs. the aim of the study is to accurately describe the impact of scd on quality of life of patients living in france, or their family (for minor patients). the consequences of the disease on professional life, education and material condition of patients or their parents will be described by the patients themselves.

this is a retrospective study. patients or parents of minor patients living in france and suffering from scd will be informed about the study and enrolled during their usual follow-up, or by patients' associations. they will be asked to answer an anonymous survey online relating to their whole life-course with scd and exploring different aspects of the consequences of the disease on their life. it contains 4 different sections: 1. socio-demographic questions to establish a respondent profile 2. health status of the respondent to establish the severity of the disease 3. education, professional life, material and economic situation 4. quality of life through mos sf-36 questionnaire this is a one-shot survey, which will take approximatively 20 to 30 minutes to answer by the respondent.

Eligibility criteria:
inclusion criteria: * 18 years or older * diagnosed with scd or parent of a minor child diagnosed with scd * able to speak and understand french * willing to participate to the study exclusion criteria: * person having serious difficulties to read or speak french, unable to answer the questions * person suffering from other chronic disease which could bias the representation they have about scd * patient cured with a bone marrow transplant * patient with mental disorder preventing the patient to understand the study

Keywords: sickle-cell disease quality of life education socio-professional integration france
sb-497115 (oral thrombopoietin receptor agonist) versus placebo in adults with refractory immune thrombocytopenic purpura (itp)

Conditions: Purpura, Thrombocytopaenic, Idiopathic

Summary: this study is a double-blind, randomized, placebo-controlled, parallel group, repeat-dose, study conducted in two parts (part a and part b) examining 30, 50, and 75 mg doses of sb-497115-gr as a treatment for patients with itp who have failed prior therapy. the study is designed to determine the proportion of patients with a platelet count =50,000/µl after 42 days. in part b, 99 newly-recruited subjects will be randomized to one of two dosing arms in a 2:1 ratio of active:placebo. during the 6 week study period, subjects will start on placebo or active drug (50 mg) and may have a dose increase to 75 mg based upon their platelet count at day 22.

a double-blind, randomized, placebo-controlled, parallel group study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of sb-497119-gr, a thrombopoietin receptor agonist, administered at 30, 50, and 75 mg as oral tablets once-daily for 6 weeks to adult male and female subjects with refractory, chronic immune thrombocytopenia purpura

Eligibility criteria:
inclusion criteria: * patients with chronic low platelet count (less than 30,000/µl) for 6 months who have failed at least one treatment for chronic low platelet count. * patients receiving chronic maintenance steroid therapy must have received a stable dose for at least 1 month. * normal pt and ptt. exclusion criteria: * history of clotting disorder. * females who are pregnant or are receiving hormone replacement therapy or systemic contraceptives. * history of alcohol/drug abuse or dependence within 1 year. * use of aspirin, aspirin-containing compounds, salicylates, antacids, rosuvastatin, pravastatin, non-steroidal anti-inflammatory drugs during the study and within 3 weeks prior to starting the study. * history of hiv infection or active infection with hepatitis b or c.

Keywords: thrombopoietin immune thrombocytopenic purpura platelets chronic thrombocytopenia
topical timolol: a comparison of surgical outcomes

Conditions: Wound Heal

Summary: the use of topical beta-blockers, such as 0.25% timolol, in promoting wound healing is currently emerging in the literature. the investigators will enroll 30 participants in a split scar study who have their skin cancer surgically removed resulting in a linear wound equal to or longer than 4cm. the objective of this randomized study is to determine the safety and efficacy of 0.25% timolol in promoting wound healing in wound closed primarily greater than or equal to 1.5 cm.

topical timolol has shown in case series to improve healing time and cosmetic outcome of ulcerated or non-healing wounds with improved cosmetic outcome when compared to standard wound care. there is currently no research detailing if this improved outcome is applicable when used with wounds approximated with sutures. mechanism of action is not fully elucidated but improved keratinocyte migration and suppression of the inflammatory cascade is thought to improve wound healing. skin cancer surgeries have morbidity for patients as they are often in cosmetically sensitive locations. improving cosmetic outcomes of surgical scars could improve patient outcomes and overall satisfaction. the goal of this study is to determine if topical timolol will improve long-term cosmetic outcomes of surgical scars and thereby improve patient outcomes. there is great variability in how a surgical site heals depending on patient factors as well as surgical site location. the investigators will perform a split scar study to allow each patient to be their own control to account for this variability. to assess the efficacy and safety of topically applied 0.25% timolol in promoting wound healing in surgical primary linear wound greater than or equal to 4cm versus standard of care (soc) by: 1. evaluating cosmetic outcomes of surgical wounds in terms of blinded physician and patient assessment at 30 days and 90days following suture removal 2. evaluating patient discomfort by patient questionnaire. 3. determining the side effects associated to 0.25% topical timolol versus soc;

Eligibility criteria:
inclusion criteria: * skin wounds greater than or equal to 4cm, closed primarily and linearly following standard excision or mohs exclusion criteria: * past medical history of psoriasis * known history of sensitivity to beta blockers or topical timolol * pregnant women

Keywords: timolol wound healing surgical wounds
pulmonary embolism as a cause of copd exacerbations

Conditions: Pulmonary Embolism; Chronic Obstructive Pulmonary Disease

Summary: the primary objective is to demonstrate the clinical benefits of an active strategy for the diagnosis and treatment of pe compared to usual care in patients with unexplained exacerbations of copd who require hospital admission. the secondary objective is to assess the safety of an active strategy for the diagnosis and treatment of pe compared to usual care in patients with unexplained exacerbations of copd who require hospital admission.


Eligibility criteria:
inclusion criteria: * confirmation of copd according to separ-alt criteria: post-bronchodilator forced expiratory volume in one second (fev1)/forced vital capacity (fvc) \< 0.7; * hospital admission because copd exacerbation without initial clinical suspicion of pe in the emergency department (according by the emergency department physician evaluation). exclusion criteria: * contraindication to multidetector computed tomographic angiography (allergy to intravenous contrast medium, or renal failure defined as a creatinine clearance less than 30 ml/min, according to the cockcroft-gault formula) * informed consent denied * pregnancy * life expectancy less than 3 months * anticoagulant therapy at the time of hospital admission * diagnosis of pneumothorax, or pneumonia (fever, and purulent sputum, and new infiltrate in chest x-ray) * diagnosis of lower respiratory tract infection (fever \[\>37.8ºc\], increased sputum volume and/or increased sputum purulence). * indication of invasive mechanical ventilation at the time of hospital admission; * impossibility for follow-up.

Keywords: venous thromboembolism copd exacerbations anticoagulation mortality
treatment of atrofic striae with percutaneous collagen induction therapy versus fractional nonablative laser

Conditions: Striae Distensae

Summary: as atrophic striae are common dermatological conditions. various therapeutic modalities have been employed in the treatment of striae distensae, mainly in striae rubra. there are few studies that include the treatment of striae alba. the non-ablative fractionated laser and, more recently, microneedling are two distinct treatments, but they are widely used in dermatologist practice. the present randomized clinical trial is aimed at evaluating and evaluating the response of microneedle and fractional non-ablative laser nd-yap 1340 in the treatment of abdominal striae alba.

twenty patients will be treated at the dermatologic clinic of the hospital de clínicas de porto alegre (hcpa). each patient will be treated with laser and microneedle at the same time, being applied a therapeutic procedure in each part of the abdomen (divided lengthwise and in equal parts). each part of the abdomen will be randomized for the treatment of laser or microneedling with the help of the excel 2013 program. the investigator responsible for procedures and patients are the only ones with unblinded assessment in relation to the side of each treatment. there will be 5 sessions with monthly intervals of the proposed treatments. the nd-yap 1340-nm laser will be used, and in the other segment of the abdomen, the dermaroller 2.5 mm was applied. photographic records of patients will be performed at pre-treatment and 1 month after the third and fifth sessions. the questionnaires will be applied to assess the quality of life in dermatology dlqi (dermatology life quality index). two independent and blind evaluators for the type of treatment will apply in the global aesthetic scale (gais) in the evaluation of photographic records. cutaneous biopsies for histopathological evaluation will be performed with a punch 3 mm of each part of the abdomen at pretreatment. two experienced pathologists will evaluate the measurements of the epidermis and the collagen and elastic fibers of the skin.

Eligibility criteria:
inclusion criteria: * female patients, * age 18 and over; * presenting with abdominal striae rubra diagnosed after clinical examination; * patients with weight stability in the last four months; * patients with fitzpatrick iii or iv phototype. exclusion criteria: * pregnant women; * childbirth for less than 12 months; * history of keloid scars; * presence of localized or systemic infection; * presence of immunosuppression; * use of photosensitizing medications; * use of systemic steroids; * use of oral isotretinoin in the last 12 months; * history of diseases of collagen or elastic fibers; * hypersensitivity to infiltrative or topical anesthetics; * patients who have been treated for striae distensae in the last year; * presence of sun exposure during the study.

Keywords: striae alba microneedling fractional nonablative laser dermaroller nd-yap 1340nm laser percutaneous collagen induction therapy
a study to assess the safety and efficacy of oral etrasimod in adult participants with eosinophilic esophagitis

Conditions: Eosinophilic Esophagitis

Summary: the purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for active eosinophilic esophagitis (eoe) in adult participants.


Eligibility criteria:
inclusion criteria: * have an eosinophilic esophagitis (eoe) diagnosis prior to screening and histologically active disease with an esophageal peak eosinophil count (pec) of ≥ 15 eosinophils per high powered field (eos/hpf) * have dysphagia, defined as solid food going down slowly or getting stuck in the throat with an average frequency of ≥ 2 episodes per week over 2 weeks during the screening period inclusion criteria for the extension treatment period * completion of the week 24 study visit \[including esophagogastroduodenoscopy (egd)\] * compliance with study procedures during the double-blind treatment period as assessed by the investigator * no notable safety concerns during the double-blind treatment period, as determined by the investigator * willing to comply with all study visits and procedures for the extension treatment period exclusion criteria: * history of any of the non-eoe conditions or procedures that may interfere with the evaluation of or affect the histologic (eg eosinophilic gastritis), endoscopic (eg, high-grade esophageal stenosis), or symptom endpoints (eg, esophageal resection) of the study * undergone dilation of an esophageal stricture within 12 weeks prior to screening egd * use of corticosteroids for the treatment of eoe within 8 weeks prior to screening egd * discontinue, initiate, or change dosing (dosage/frequency) of the following therapies for eoe within 8 weeks prior to screening egd. participants on any of the following therapy need to stay on a stable regimen during study participation: 1. elemental diet 2. eoe food trigger elimination diet 3. proton pump inhibitor (ppi) therapy * used any immunotherapy/desensitization including oral immunotherapy (oit) or sublingual immunotherapy (slit) within 12 months prior to the screening egd. note: stable (ie, ≥ 6 months prior to the screening egd) subcutaneous immunotherapy (scit) is permitted. participants on scit need to stay on a stable treatment during study participation * used any protocol-specified immunomodulatory therapies within the protocol-specified timeframe prior to baseline (eg, dupilumab, benralizumab, omalizumab, or infliximab within 12 weeks; a sphingosine-1-phosphate receptor modulator at any time) * use of any investigational agent or device within 12 weeks prior to baseline * females who are pregnant

Keywords: eosinophilic esophagitis esophageal eosinophilia etrasimod apd334 eoe eosinophilic oesophagitis
influence of hospital volume on mortality and length of hospital stay after pancreatic resection in switzerland

Conditions: Pancreatic Diseases

Summary: the effect of centralisation measures on the operative outcomes after pancreatic resection in switzerland has not been highlighted yet. this study aims to investigate the influence of the annual hospital specific case load of pancreatic resection on short-term postoperative outcomes.


Eligibility criteria:
inclusion criteria: * all patients with pancreatic resection in switzerland between 2013 and 2022 exclusion criteria: * incomplete case documentation * age under 20 years * other hospitals than general or surgical hospitals * no index operation
causes of non-invasive fungal sinusitis as presented in sohag university hospital

Conditions: Sinus Infection

Summary: in this study, the investigators will collect data from patients with non-invasive fungal sinusitis to know what causes it

in this study, the investigators will try to know the epidemiology of noninvasive fungal sinusitis, especially in recurrent cases this study will be carried out at sohag university hospital. retrospective study study period: 5 years (from august 2016 to august 2021. )

Eligibility criteria:
inclusion criteria: * patients with acute fungal sinusitis. * patients with chronic granulomatous sinusitis. * patients with sinus mycetomas. exclusion criteria: * immunocompromised patients. * invasive fungal sinusitis.
a study to evaluate the efficacy and safety of alks 9072 (also known as aripiprazole lauroxil, alks 9070, or aristada) in subjects with schizophrenia

Conditions: Schizophrenia

Summary: the study will determine the efficacy of alks 9072 (also known as aripiprazole lauroxil or alks 9070) for the treatment of schizophrenia in subjects experiencing an acute exacerbation.


Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia according to dsm-iv-tr criteria * has been able to achieve outpatient status for more than 3 months in the past year * body mass index (bmi) of 18.5 to 40.0 kg/m2 (inclusive) * resides in a stable living situation * willing and able to be confined to an inpatient study unit for 2 weeks or longer exclusion criteria: * history of poor or inadequate clinical response to treatment with aripiprazole * history of treatment resistance * known or suspected intolerance of, allergy, or hypersensitivity to aripiprazole, its ingredients, other antipsychotic agent, or intralipid (including peanuts, soy, egg, or glycerol) * diagnosis of current substance dependence (including alcohol) * pregnant, lactating, or breastfeeding * receipt of any antipsychotic medication by im injection within 60 days before screening * current involuntary hospitalization or incarceration * hospitalized for more than 30 days during the 90 days before screening additional inclusion/exclusion criteria may apply.

Keywords: alkermes schizophrenia alks 9072 alks 9070 aripiprazole lauroxil